Bradford 01274 350 800
Leeds 0113 849 4000
Huddersfield 01484 915 000

Pioneer in fight against major diseases in £7m share placing

Schofield Sweeney advised Manchester-based biotech company C4X Discovery Holdings – a pioneer in the battle against rheumatoid arthritis and Parkinson’s disease - on its £7m share placing, putting 22% of its capital up for grabs.

The move has been prompted by the continuing increase in global licensing of pre-clinical stage assets with the number of deals greater than $10m increasing from 50 in 2012 to 78 in 2015 and the value of upfront payments increasing by 289%.

C4X Discovery aims to do this by exploiting its cutting-edge proprietary technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas.

The company's goal is to drive returns through early-stage revenue-generating licensing deals for its high value pre-clinical asset portfolio with the pharmaceutical industry.

Chris Schofield, Chris Blantern and Jessica Fielden advised C4X.

About the Author

Chris Blantern


Chris has a wealth of experience acting for a wide range of clients from small to medium sized enterprises…

View Profile View all